In a milestone for Broward Health in Ft. Lauderdale, Fla., Jose L. Baez-Escudero, M.D., chief of cardiology and electrophysiology, has performed the first atrial fibrillation (AFib) ablation in Broward County using the VARIPULSE Pulsed Field Ablation (PFA) Catheter, marking a significant advancement in the treatment of cardiac arrhythmias for patients.

March 13, 2026 — According to a new research study published by Vyansa Intelligence, the Cardiovascular Devices Market in the United States is projected to grow at a CAGR of around 9.35% during 2026–2032. The market expansion is primarily attributed to the increasing prevalence of cardiovascular diseases, rapid technological advancements in minimally invasive cardiac procedures and the growing adoption of advanced diagnostic and therapeutic cardiovascular devices across healthcare facilities in the country.

Key Takeaways

March 18, 2026 — Circle Cardiovascular Imaging (Circle CVI) has announced the expansion of its cvi42 cardiovascular imaging platform to include advanced Vascular CT analysis, further extending the platform’s capabilities across cardiovascular imaging workflows. The new solution is enabled through a collaboration with Astute Imaging, whose AI-driven vascular analysis technology has been integrated into the cvi42 ecosystem.

March 19, 2026 — Endovascular Engineering, Inc. has announced that two abstracts related to the ENGULF study and the Hēlo Platform have been accepted as late-breaking podium presentations at the Society of Interventional Radiology (SIR) Annual Scientific Meeting and the Society for Cardiovascular Angiography & Interventions (SCAI) Scientific Sessions, both taking place in April.

The Hēlo Platform is intended to treat pulmonary embolism and remove clots from peripheral veins.

March 19, 2026 — Heart disease is the leading cause of adult death worldwide, making cardiovascular disease diagnosis and management a global health priority. An echocardiogram, or cardiac ultrasound, is one of the most commonly used imaging tools employed by physicians to diagnose a variety of heart diseases and conditions.  

Feb. 9, 2026 —The International Cardio-Oncology Society has awarded University Hospitals in Cleveland, Ohio, with a Center of Excellence designation in recognition of its ongoing support of patients with cancer. This Gold Status certification, the society’s highest designation, recognizes the institute for its commitment to cardiology services for patients with cancer for whom life-saving treatments may cause cardiac problems.

March 17, 2026 — Empassion Health, Inc. has announced a strategic partnership with Karoo Health Inc, America’s Cardiac Solution.

The partnership brings together two organizations with deep expertise in different stages of complex illness to better support patients living with advanced cardiovascular and other serious illness conditions. 

March 16, 2026 — The American Society for Preventive Cardiology (ASPC) will host its 2026 Virtual Imaging Symposium, a half-day educational program dedicated to advancing the role of cardiovascular imaging in disease prevention. The event will take place on April 25, 2026, bringing together leading experts to explore cutting-edge imaging tools and their clinical applications in preventive cardiology.

March 17, 2026 — Stern Cardiovascular and Atria Health have announced a strategic partnership that will accelerate access to advanced, physician-led cardiovascular care across Tennessee, Mississippi, Arkansas and surrounding regions. The collaboration brings together Stern's clinical leadership and Atria Health's operational expertise to support Stern's expanded services, new locations, and physician recruitment.

March 16, 2026 — Cytokinetics has announced four presentations related to Myqorzo (aficamten) at the American College of Cardiology (ACC) Annual Scientific Session & Expo, March 28–30, 2026, New Orleans, LA. Recently approved for the treating adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) by the U.S. Food and Drug Administration, European Commission and the China National Medical Products Administration, Myqorzos an allosteric and reversible inhibitor of cardiac myosin motor activity.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now